mitoxantrone has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 220 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have studied the plasma and peripheral leukocyte pharmacokinetics of mitoxantrone associated, in a high-dose regimen, with cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation." | 9.07 | Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. ( Attal, M; Bugat, R; Canal, P; Chatelut, E; Guichard, S; Houin, G; Huguet, F; Laurent, G; Muller, C; Schlaifer, D, 1993) |
| "Prior studies of the combination of fludarabine, mitoxantrone and dexamethasone have yielded high response rates but are associated with a significant risk of opportunistic infections, predominantly Pneumocystis Carinii pneumonia (PCP) requiring routine prophylaxis." | 5.09 | Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. ( Fox, RM; Grigg, AP; Seymour, JF; Szer, J, 2001) |
| " Three cohorts of ten patients with breast cancer (BC) or non-Hodgkin's lymphoma (NHL) received escalating doses of NOV, 60, 75 and 90 mg m(-2) plus melphalan (L-PAM), 140-180 mg m(-2), with PBPC rescue 96 h after NOV." | 5.08 | High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule. ( Ballestrero, A; Basta, P; Brema, F; Esposito, M; Ferrando, F; Friedman, D; Garuti, A; Gonella, R; Mela, GS; Patrone, F; Puglisi, M; Sessarego, M; Sorice, G; Vannozzi, MO, 1997) |
| "We have studied the plasma and peripheral leukocyte pharmacokinetics of mitoxantrone associated, in a high-dose regimen, with cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation." | 5.07 | Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. ( Attal, M; Bugat, R; Canal, P; Chatelut, E; Guichard, S; Houin, G; Huguet, F; Laurent, G; Muller, C; Schlaifer, D, 1993) |
| " Fifty-five breast cancer patients treated with mitoxantrone, methotrexate and 5-fluorouracil gave a response rate of 52." | 5.06 | [Mitoxantrone containing multi-drug chemotherapy in the management of malignancies. Collaborative Group for Clinical Trial of Mitoxantrone]. ( , 1989) |
| " Patients who proceeded to haematopoietic stem cell transplants (HDTs) received conditioning therapy with BEAM [for the Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma (NHL) groups], or melphalan 100 mg/m2 and mitoxantrone [for the multiple myeloma (MM) patients]." | 3.73 | Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. ( Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R, 2005) |
| "Nineteen patients with metastatic breast cancer and six patients with refractory non-Hodgkin's lymphoma were initially treated with etoposide (VP-16) (2 gm/m2) and granulocyte-colony stimulating factor (G-CSF)." | 3.69 | Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. ( Blume, KG; Chao, NJ; Hoyle, CF; Kusnierz-Glaz, CR; Long, GD; Negrin, RS; Schriber, JR, 1995) |
| "Follicular lymphoma is the most common form of lymphoma in Europe and the USA." | 2.73 | Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). ( Baccarani, M; Cabras, MG; De Luca, S; De Renzo, A; Derenzini, E; Fabbri, A; Fanti, S; Fattori, P; Fina, M; Gobbi, M; Guardigni, L; Marchi, E; Musuraca, G; Pellegrini, C; Perotti, A; Piccaluga, PP; Pileri, S; Pulsoni, A; Rigacci, L; Ronconi, S; Stefoni, V; Tani, M; Voso, MT; Zaccaria, A; Zinzani, PL, 2008) |
| "Rituximab, a chimeric monoclonal antibody, produces response rates of up to 73% in patients with previously untreated indolent non-Hodgkin's lymphoma (NHL), and has high activity when combined with chemotherapy." | 2.71 | Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. ( Christodoulou, C; Dimopoulos, M; Economopoulos, T; Fountzilas, G; Hamilos, G; Kalantzis, D; Nicolaides, C; Papageorgiou, E; Pavlidis, N, 2003) |
| "Two cases of acute myelogenous leukemia (AML) were recorded, both in the iCNOP arm (p = 0." | 2.71 | A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma. ( Angelopoulou, MK; Bourantas, KL; Christopoulos, G; Grigorakis, V; Kalmantis, T; Kokkinis, G; Korantzis, J; Michalis, E; Mihalakeas, I; Pangalis, GA; Papayiannis, A; Repousis, P; Roussou, P; Siakantaris, MP; Stamatellou, M; Stefanoudakis, E; Symeonidis, A; Vassilakopoulos, TP; Vrakidou, E, 2003) |
| "Acute renal failure and bacterial infection occurred as non-hematologic dose limiting toxicities." | 2.70 | A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation. ( de Magalhaes-Silverman, M; Gingrich, RD; Hayashi, M; Hohl, RJ; Lee, CK; Schlueter, A; Strauss, RG, 2002) |
| " No toxic deaths have occurred." | 2.69 | Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma. ( Budel, L; Doorduijn, JK; Löwenberg, B; Sonneveld, P; Spruit, P; van Der Holt, B; van't Veer, M, 2000) |
| "Evaluate response, duration of response, and toxicity of paclitaxel in combination with other drugs known to be effective in non-Hodgkin's lymphoma (NHL)." | 2.69 | Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. ( Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, A; Rodriguez, J; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A, 1999) |
| " The maximal acceptable dosage of mitoxantrone was 10 mg/m2 x 2 due to serious hematologic toxicity." | 2.69 | Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. ( Berinstein, NL; Franssen, E; Haq, R; Sawka, CA, 1999) |
| "Treatment of Hodgkin's disease (HD) and non-Hodgkin lymphomas (NHL) is still unsatisfactory in patients resistant to primary therapy or those with early relapses." | 2.69 | [Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells]. ( Adam, Z; Hájek, R; Hejlová, N; Klabusay, M; Korístek, Z; Krahulcová, E; Král, Z; Mayer, J; Müllerová, I; Navrátil, M; Penka, M; Tomíska, M; Vásová, I; Vodvárka, P; Vorlícek, J, 1998) |
| "Ara-C was administered at a dosage of 3 gm/sqm for 2-hour intravenous infusion every 12 hours from day 1 to day 4 (8 doses), and mitoxantrone was given at a dosage of 6 mg/sqm/day for 1-hour intravenous infusion from day 1 to day 5." | 2.68 | High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma. ( Chen, PM; Chiou, TJ; Fan, S; Liu, JH; Tzeng, CH; Wang, WS, 1996) |
| " NO was applied at a dosage of 10 mg/m2/day on days 2 and 3 and AC at 3 g/m2/12h on days 1 and 2." | 2.67 | Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study. ( Andreesen, R; Del Valle, F; Engelhard, M; Fiedler, W; Haas, R; Hiddemann, W; Ho, AD; Rückle, H; Schlimok, G; Thiel, E, 1990) |
| "Objective response rates were 21% in breast cancer, 36% in non-Hodgkin's lymphoma, 56% in acute lymphocytic leukemia, 14% in acute nonlymphocytic leukemia, 31% in gastric cancer and 5% in primary hepatic cancer." | 2.66 | [Phase II clinical trial on mitoxantrone]. ( Gao, HR, 1989) |
| "Mitoxantrone is an effective agent in refractory NHL and should be taken into consideration in the design of salvage regimens." | 2.66 | Mitoxantrone: an active agent in refractory non-Hodgkin's lymphomas. ( Bajetta, E; Bonadonna, G; Buzzoni, R; Valagussa, P, 1988) |
| "Mitoxantrone has a broad anti-tumour activity including lymphoma with potentially less cardiotoxicity than doxorubicin, which may be of particular importance in elderly patients." | 2.44 | CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis). ( Ahlbom, A; Anders, A; Andersson, T; Björkholm, M; Eva, O; Magnus, B; Ösby, E; Tomas, A, 2008) |
| "Most patients with follicular lymphoma respond to therapy, and the average survival time in large series is approximately 10 years." | 2.42 | Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. ( Armitage, JO; Hoelzer, D; Rummel, MJ; Tobinai, K, 2004) |
| "A 47 year old woman with a MALT lymphoma affecting the breast exclusively is reported." | 2.40 | [Primary MALT-type lymphoma of the breast]. ( Campo, E; Cervantes, F; Esteve, J; Montserrat, E; Rafel, M; Serra, A; Velasco, M, 1998) |
| "Histopathological subtypes consist of Burkitt's lymphoma (BL) in 32 (43." | 1.48 | Demographics and Outome in Paediatric Non-Hodgkin Lymphoma: Single Centre Experience at The Children Hospital Lahore, Pakistan. ( Anwar, S; Faizan, M; Khan, S, 2018) |
| "There were 32 small lymphocytic lymphomas and 111 marginal zone lymphomas." | 1.42 | Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients. ( Argnani, L; Broccoli, A; Casadei, B; Gandolfi, L; Maglie, R; Pellegrini, C; Pileri, S; Stefoni, V; Zinzani, PL, 2015) |
| " TMJ is a safe and effective regimen when used as a part of autologous stem cell transplant for patients with HD and NHL." | 1.32 | High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors. ( Ahmed, T; Hoang, A; Kancherla, R; Liu, D; Qureshi, Z; Seiter, K; Waheed, F, 2004) |
| "Seventeen patients had small lymphocytic lymphoma (SLL), 29 had follicular lymphoma (FL), 10 of them with histologic transformation." | 1.31 | Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. ( Caracciolo, D; Corradini, P; Cuttica, A; Gavarotti, P; Ladetto, M; Novero, D; Pileri, A; Rossi, G; Tarella, C; Zallio, F, 2000) |
| "We describe two cases of interstitial lung disease in patients with non-Hodgkin's lymphoma who were treated with combination chemotherapy including mitozantrone." | 1.30 | Interstitial pneumonitis following mitozantrone, chlorambucil and prednisolone (MCP) chemotherapy. ( Johnson, S; Nicholson, AG; Rule, S; Stone, R; Tighe, M; Tomlinson, J, 1999) |
| "Mitoxantrone was dose-escalated in increments of 2." | 1.29 | Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. ( Kosty, M; Lee, T; Piro, L; Saven, A, 1996) |
| "Chylothorax is an accumulation of thoracic lymph or chyle in the pleural cavity." | 1.29 | Intrapleural bleomycin in the treatment of chylothorax. ( Aasebø, U; Norum, J, 1994) |
| "In stage III and IV Hodgkin's disease, for example, an age-adjusted COPP regimen may be adopted." | 1.28 | [Treatment of elderly patients with hematological malignancies]. ( Mizoguchi, H; Saito, H, 1992) |
| " In the second study (NOAC II), the dosage of cytarabine was escalated to 3 g/m2/12 h on days 1 and 2 (4 doses) while mitoxantrone remained 10 mg/m2/d on days 2 and 3." | 1.28 | Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma. ( Andreesen, R; Del Valle, F; Engelhard, M; Fiedler, W; Haas, R; Hiddemann, W; Ho, AD; Rückle, H; Schlimok, G; Thiel, E, 1990) |
| "Myelosuppression with subsequent infections was the major toxicity of this regimen." | 1.28 | Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma. ( del Valle, F; Dörken, B; Hiddemann, W; Ho, AD; Hunstein, W; Meusers, P; Rückle, H; Schlimok, G; Schwammborn, J; Thiel, E, 1989) |
| "However, cardiac failure, the primary cause of death in four patients, was associated with coagulative fiber necroses and contraction band necroses, which may be related to acute cyclophosphamide toxicity." | 1.27 | Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor. ( Dörken, B; Körbling, M; Mall, G; von Herbay, A, 1988) |
| "One of 11 patients with Hodgkin's disease, 2 of 12 with favorable-histology non-Hodgkin's lymphoma, 4 of 27 with unfavorable-histology non-Hodgkin's lymphoma, and 1 of 11 with chronic lymphocytic leukemia showed a response." | 1.27 | Weekly mitoxantrone therapy of Hodgkin's disease, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. A Southeastern Cancer Study Group Trial. ( Bartolucci, AA; Gams, RA; Keller, JW; Omura, GA, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (6.36) | 18.7374 |
| 1990's | 113 (51.36) | 18.2507 |
| 2000's | 85 (38.64) | 29.6817 |
| 2010's | 8 (3.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nastoupil, LJ | 1 |
| McLaughlin, P | 11 |
| Feng, L | 1 |
| Neelapu, SS | 1 |
| Samaniego, F | 1 |
| Hagemeister, FB | 9 |
| Ayala, A | 2 |
| Romaguera, JE | 6 |
| Goy, AH | 1 |
| Neal, E | 1 |
| Wang, M | 1 |
| Fayad, L | 2 |
| Fanale, MA | 1 |
| Oki, Y | 1 |
| Westin, JR | 1 |
| Rodriguez, MA | 11 |
| Cabanillas, F | 13 |
| Fowler, NH | 1 |
| Faizan, M | 1 |
| Anwar, S | 1 |
| Khan, S | 1 |
| Marquardt, TM | 1 |
| Lindley, SES | 1 |
| Smith, AN | 1 |
| Cannon, CM | 1 |
| Rodriguez, CO | 1 |
| Thamm, DH | 1 |
| Childress, MO | 1 |
| Northrup, NC | 1 |
| Zinzani, PL | 10 |
| Pellegrini, C | 3 |
| Broccoli, A | 2 |
| Gandolfi, L | 2 |
| Stefoni, V | 6 |
| Casadei, B | 1 |
| Maglie, R | 1 |
| Argnani, L | 2 |
| Pileri, S | 2 |
| Cohen, JB | 1 |
| Bucur, S | 1 |
| Winton, EF | 1 |
| Sinha, R | 1 |
| Heffner, LT | 1 |
| King, N | 1 |
| Lonial, S | 1 |
| Langston, AA | 1 |
| Waller, EK | 1 |
| Hutchison-Rzepka, A | 1 |
| Colbert, A | 1 |
| Lechowicz, MJ | 1 |
| Flowers, CR | 1 |
| Zwick, C | 1 |
| Birkmann, J | 2 |
| Peter, N | 1 |
| Bodenstein, H | 2 |
| Fuchs, R | 1 |
| Hänel, M | 2 |
| Reiser, M | 1 |
| Hensel, M | 1 |
| Clemens, M | 1 |
| Zeynalova, S | 1 |
| Ziepert, M | 1 |
| Pfreundschuh, M | 1 |
| Jonathan, F | 1 |
| Gobbi, PG | 1 |
| Valentino, F | 1 |
| Lambelet, P | 1 |
| Perfetti, V | 1 |
| Bergamaschi, G | 1 |
| Girino, M | 1 |
| Corazza, GR | 1 |
| Sharma, R | 1 |
| Cunningham, D | 3 |
| Smith, P | 3 |
| Robertson, G | 1 |
| Dent, O | 1 |
| Clarke, SJ | 1 |
| Dincol, D | 2 |
| Buyukcelik, A | 1 |
| Dogan, M | 1 |
| Akbulut, H | 2 |
| Samur, M | 1 |
| Demirkazik, A | 2 |
| Senler, FC | 1 |
| Onur, H | 1 |
| Icli, F | 2 |
| Fanti, S | 3 |
| Derenzini, E | 3 |
| Quirini, F | 1 |
| Baccarani, M | 4 |
| Monjanel, H | 1 |
| Deconinck, E | 2 |
| Perrodeau, E | 1 |
| Gastinne, T | 1 |
| Delwail, V | 3 |
| Moreau, A | 1 |
| François, S | 1 |
| Berthou, C | 2 |
| Gyan, E | 1 |
| Milpied, N | 1 |
| Schmitt, B | 1 |
| Wendtner, CM | 1 |
| Bergmann, M | 1 |
| Busch, R | 1 |
| Franke, A | 2 |
| Pasold, R | 2 |
| Schlag, R | 1 |
| Hopfinger, G | 1 |
| Hiddemann, W | 13 |
| Emmerich, B | 1 |
| Hallek, M | 1 |
| Handa, H | 1 |
| Motohashi, S | 1 |
| Isozumi, K | 1 |
| Komatsumoto, S | 1 |
| Nara, M | 1 |
| Vose, JM | 1 |
| Weisenburger, DD | 1 |
| Lynch, JC | 1 |
| Bierman, PJ | 1 |
| Chan, JC | 1 |
| Bast, M | 1 |
| Aoun, P | 1 |
| Bociek, G | 1 |
| Greiner, T | 1 |
| Armitage, JO | 2 |
| Rummel, MJ | 2 |
| Chow, KU | 1 |
| Karakas, T | 1 |
| Jäger, E | 1 |
| Mezger, J | 1 |
| von Grünhagen, U | 1 |
| Schalk, KP | 1 |
| Burkhard, O | 1 |
| Hansmann, ML | 1 |
| Ritzel, H | 1 |
| Bergmann, L | 1 |
| Hoelzer, D | 2 |
| Mitrou, PS | 1 |
| Lee, CK | 1 |
| de Magalhaes-Silverman, M | 1 |
| Hayashi, M | 1 |
| Schlueter, A | 1 |
| Strauss, RG | 1 |
| Hohl, RJ | 1 |
| Gingrich, RD | 1 |
| Gherlinzoni, F | 6 |
| Storti, S | 3 |
| Zaccaria, A | 3 |
| Pavone, E | 3 |
| Moretti, L | 3 |
| Gentilini, P | 3 |
| Guardigni, L | 4 |
| De Renzo, A | 3 |
| Fattori, PP | 3 |
| Falini, B | 3 |
| Lauta, VM | 3 |
| Mannina, D | 1 |
| Zaja, F | 2 |
| Mazza, P | 3 |
| Volpe, E | 2 |
| Lauria, F | 1 |
| Aitini, E | 3 |
| Ciccone, F | 1 |
| Tani, M | 3 |
| Alinari, L | 1 |
| Tura, S | 7 |
| Büchler, T | 1 |
| Ferra, C | 1 |
| Virgili, N | 1 |
| Montanya, E | 1 |
| Grañena, A | 1 |
| Tsimberidou, AM | 2 |
| Younes, A | 4 |
| Sarris, A | 2 |
| Romaguera, J | 3 |
| Hess, M | 2 |
| Smith, TL | 1 |
| Yang, Y | 1 |
| Preti, A | 2 |
| Lee, MS | 2 |
| Forstpointner, R | 1 |
| Hänel, A | 2 |
| Repp, R | 1 |
| Hermann, S | 1 |
| Metzner, B | 1 |
| Pott, C | 1 |
| Hartmann, F | 1 |
| Rothmann, F | 1 |
| Böck, HP | 1 |
| Wandt, H | 1 |
| Unterhalt, M | 8 |
| Gibson, AD | 1 |
| Emmanouilides, C | 1 |
| Lill, M | 1 |
| Telatar, M | 1 |
| Rosenfelt, F | 1 |
| Grody, W | 1 |
| Territo, M | 1 |
| Rosen, P | 1 |
| Bessell, EM | 2 |
| Burton, A | 1 |
| Haynes, AP | 1 |
| Glaholm, J | 1 |
| Child, JA | 1 |
| Cullen, MH | 1 |
| Davies, JM | 2 |
| Smith, GM | 1 |
| Ellis, IO | 2 |
| Jack, A | 2 |
| Jones, EL | 1 |
| Herold, M | 1 |
| Dölken, G | 1 |
| Fiedler, F | 2 |
| Freund, M | 4 |
| Helbig, W | 1 |
| Milone, G | 1 |
| Di Raimondo, F | 1 |
| Gioi, FL | 1 |
| Palumbo, GA | 1 |
| Manenti, GO | 1 |
| Pafumi, M | 1 |
| Giustolisi, R | 1 |
| Dreyling, M | 2 |
| Velasquez, WS | 1 |
| Lew, D | 1 |
| Grogan, TM | 1 |
| Spiridonidis, CH | 1 |
| Balcerzak, SP | 1 |
| Dakhil, SR | 1 |
| Miller, TP | 2 |
| Lanier, KS | 1 |
| Chapman, RA | 1 |
| Fisher, RI | 2 |
| Economopoulos, T | 4 |
| Fountzilas, G | 4 |
| Pavlidis, N | 2 |
| Kalantzis, D | 1 |
| Papageorgiou, E | 2 |
| Christodoulou, C | 1 |
| Hamilos, G | 1 |
| Nicolaides, C | 3 |
| Dimopoulos, M | 1 |
| Pangalis, GA | 2 |
| Vassilakopoulos, TP | 1 |
| Michalis, E | 1 |
| Roussou, P | 2 |
| Vrakidou, E | 1 |
| Repousis, P | 1 |
| Angelopoulou, MK | 2 |
| Siakantaris, MP | 1 |
| Korantzis, J | 1 |
| Symeonidis, A | 1 |
| Grigorakis, V | 1 |
| Stefanoudakis, E | 1 |
| Stamatellou, M | 1 |
| Bourantas, KL | 1 |
| Kalmantis, T | 1 |
| Christopoulos, G | 1 |
| Kokkinis, G | 1 |
| Mihalakeas, I | 1 |
| Papayiannis, A | 1 |
| Hainsworth, JD | 1 |
| Litchy, S | 1 |
| Lamb, MR | 1 |
| Rodriguez, GI | 1 |
| Scroggin, C | 1 |
| Greco, FA | 1 |
| Lyman, GH | 2 |
| Delgado, DJ | 2 |
| Mantzios, G | 2 |
| Tsirigotis, P | 1 |
| Veliou, F | 1 |
| Boutsikakis, I | 1 |
| Petraki, L | 1 |
| Kolovos, J | 1 |
| Papageorgiou, S | 2 |
| Robos, Y | 1 |
| Froehner, M | 1 |
| Haase, M | 1 |
| Hakenberg, OW | 1 |
| Wirth, MP | 1 |
| Ma, SY | 1 |
| Au, WY | 1 |
| Chim, CS | 1 |
| Lie, AK | 1 |
| Lam, CC | 1 |
| Tse, E | 1 |
| Leung, AY | 1 |
| Liang, R | 1 |
| Kwong, YL | 1 |
| Bordonaro, R | 1 |
| Petralia, G | 1 |
| Restuccia, N | 1 |
| Todaro, AM | 1 |
| Serraino, D | 2 |
| Giuffrida, D | 1 |
| Cordio, S | 1 |
| Giannitto-Giorgio, C | 1 |
| Salice, P | 1 |
| Ursino, M | 1 |
| Novello, G | 1 |
| Marletta, F | 1 |
| Manusia, M | 1 |
| Tobinai, K | 1 |
| Osby, E | 3 |
| Askling, J | 1 |
| Landgren, O | 1 |
| Dickman, PW | 1 |
| Ekbom, A | 1 |
| Björkholm, M | 3 |
| Hendry, L | 1 |
| Bowen, A | 1 |
| Matutes, E | 1 |
| Swansbury, J | 1 |
| Catovsky, D | 1 |
| Dale, DC | 1 |
| Friedberg, J | 1 |
| Crawford, J | 1 |
| Waheed, F | 1 |
| Kancherla, R | 2 |
| Seiter, K | 2 |
| Liu, D | 1 |
| Qureshi, Z | 1 |
| Hoang, A | 1 |
| Ahmed, T | 1 |
| Wöhrer, S | 1 |
| Raderer, M | 1 |
| Kaufmann, H | 1 |
| Hejna, M | 1 |
| Chott, A | 1 |
| Zielinski, CC | 1 |
| Drach, J | 1 |
| Rigacci, L | 3 |
| Carrai, V | 1 |
| Nassi, L | 1 |
| Alterini, R | 2 |
| Longo, G | 2 |
| Bernardi, F | 2 |
| Bosi, A | 1 |
| Di Bella, N | 1 |
| Reynolds, C | 1 |
| Faragher, D | 1 |
| Muscato, J | 1 |
| Boehm, KA | 1 |
| Asmar, L | 1 |
| Ishii, K | 1 |
| Yamamoto, Y | 1 |
| Shigeki, T | 1 |
| Kitayama, H | 1 |
| Hayashi, K | 3 |
| Hirose, A | 1 |
| Ohta, T | 1 |
| Mugitani, A | 1 |
| Fujino, H | 1 |
| Yagi, T | 1 |
| Hirai, M | 1 |
| Teshima, H | 1 |
| Katsurada, T | 1 |
| Urase, F | 1 |
| Kitajima, H | 1 |
| Foussard, C | 2 |
| Colombat, P | 1 |
| Maisonneuve, H | 2 |
| Gressin, R | 2 |
| Rousselet, MC | 1 |
| Rachieru, P | 1 |
| Pignon, B | 1 |
| Mahé, B | 1 |
| Ghandour, C | 1 |
| Desablens, B | 1 |
| Casassus, P | 1 |
| Lamy, T | 1 |
| Gershanovich, ML | 1 |
| Tikhonova, VV | 1 |
| van Imhoff, GW | 1 |
| van der Holt, B | 2 |
| Mackenzie, MA | 1 |
| Van't Veer, MB | 1 |
| Wijermans, PW | 2 |
| Ossenkoppele, GJ | 1 |
| Schouten, HC | 2 |
| Sonneveld, P | 6 |
| Steijaert, MM | 1 |
| Kluin, PM | 1 |
| Kluin-Nelemans, HC | 1 |
| Verdonck, LF | 1 |
| Chamorey, E | 1 |
| Peyrade, F | 1 |
| Rossi, JF | 1 |
| Lepeu, G | 1 |
| Harrousseau, JL | 1 |
| Fabbro, M | 1 |
| Richard, B | 1 |
| Vilque, JP | 1 |
| Thyss, A | 1 |
| Clavio, M | 2 |
| Garrone, A | 1 |
| Pierri, I | 1 |
| Michelis, GL | 1 |
| Balocco, M | 1 |
| Albarello, A | 1 |
| Varaldo, R | 1 |
| Canepa, P | 1 |
| Miglino, M | 1 |
| Ballerini, F | 1 |
| Canepa, L | 1 |
| Gobbi, M | 6 |
| Enschede, SH | 1 |
| Porter, C | 1 |
| Venugopal, P | 1 |
| Gregory, SA | 2 |
| Sorá, F | 1 |
| Piccirillo, N | 1 |
| Chiusolo, P | 1 |
| Laurenti, L | 1 |
| Marra, R | 1 |
| Bartolozzi, F | 1 |
| Leone, G | 3 |
| Sica, S | 1 |
| Burton, C | 1 |
| Linch, D | 2 |
| Hoskin, P | 2 |
| Milligan, D | 1 |
| Dyer, MJ | 1 |
| Hancock, B | 2 |
| Mouncey, P | 1 |
| Qian, W | 1 |
| MacLennan, K | 2 |
| Webb, A | 1 |
| Alexandrescu, DT | 1 |
| Karri, S | 1 |
| Wiernik, PH | 2 |
| Dutcher, JP | 2 |
| Sugimoto, T | 1 |
| Matano, S | 2 |
| Nishijima, H | 1 |
| Kakuta, K | 1 |
| Inamura, K | 1 |
| Okamura, T | 1 |
| Munemoto, S | 1 |
| Satoh, S | 1 |
| Nair, R | 1 |
| Prabhash, K | 1 |
| Sengar, M | 1 |
| Bakshi, A | 1 |
| Gujral, S | 1 |
| Gupta, S | 1 |
| Parikh, P | 1 |
| Robak, T | 3 |
| Lech-Maranda, E | 2 |
| Janus, A | 1 |
| Blonski, J | 1 |
| Wierzbowska, A | 1 |
| Gora-Tybor, J | 3 |
| Weide, R | 1 |
| Hess, G | 1 |
| Köppler, H | 1 |
| Heymanns, J | 1 |
| Thomalla, J | 1 |
| Aldaoud, A | 1 |
| Losem, C | 1 |
| Schmitz, S | 1 |
| Haak, U | 1 |
| Huber, C | 1 |
| Yamanaka, R | 1 |
| Homma, J | 1 |
| Sano, M | 1 |
| Tsuchiya, N | 1 |
| Yajima, N | 1 |
| Takahashi, H | 1 |
| Shinbo, Y | 1 |
| Hasegawa, A | 1 |
| Saitoh, T | 1 |
| Tanaka, R | 1 |
| Morrison, VA | 2 |
| Musuraca, G | 2 |
| Vitolo, U | 1 |
| Perrotti, A | 1 |
| Fina, M | 2 |
| Psyrri, A | 1 |
| Tsatalas, C | 2 |
| Anagnostopoulos, A | 2 |
| Xiros, N | 1 |
| Dimopoulos, MA | 3 |
| Lü, SQ | 1 |
| Yang, JM | 1 |
| Song, XM | 1 |
| Chen, L | 1 |
| Zhang, WP | 1 |
| Ni, X | 1 |
| Xu, XQ | 1 |
| Wang, JM | 1 |
| Magnus, B | 1 |
| Andersson, T | 1 |
| Tomas, A | 1 |
| Ahlbom, A | 1 |
| Anders, A | 1 |
| Eva, O | 1 |
| Pulsoni, A | 1 |
| Perotti, A | 1 |
| De Luca, S | 1 |
| Fabbri, A | 1 |
| Voso, MT | 2 |
| Fattori, P | 1 |
| Ronconi, S | 1 |
| Cabras, MG | 1 |
| Marchi, E | 1 |
| Piccaluga, PP | 1 |
| Errante, D | 5 |
| Bianco, A | 2 |
| Aversa, SML | 1 |
| Salvagno, L | 3 |
| Karaoğuz, H | 1 |
| Cay, F | 1 |
| Arican, A | 1 |
| Haas, R | 9 |
| Ehrhardt, R | 1 |
| Witt, B | 4 |
| Goldschmidt, H | 5 |
| Hohaus, S | 2 |
| Pförsich, M | 1 |
| Ehrlich, H | 1 |
| Färber, L | 1 |
| Hunstein, W | 7 |
| Swan, F | 3 |
| Pate, O | 2 |
| Moos, M | 5 |
| Karcher, A | 2 |
| Möhle, R | 3 |
| Frühauf, S | 1 |
| Flentje, M | 3 |
| Wannenmacher, M | 4 |
| Barista, I | 2 |
| Tekuzman, G | 2 |
| Firat, D | 2 |
| Baltali, E | 1 |
| Kansu, E | 1 |
| Kars, A | 2 |
| Ozisik, Y | 1 |
| Ruacan, S | 1 |
| Uzunalimoğlu, B | 1 |
| Karaağaoğlu, E | 1 |
| Avilés, A | 1 |
| Díaz-Maqueo, JC | 2 |
| Talavera, A | 1 |
| Nambo, MJ | 1 |
| García, EL | 1 |
| Norum, J | 1 |
| Aasebø, U | 1 |
| De Lena, M | 2 |
| Ditonno, P | 1 |
| Lorusso, V | 2 |
| Brandi, M | 1 |
| Timurian, A | 1 |
| Marzullo, F | 1 |
| Ventrella, V | 1 |
| Pellecchia, A | 1 |
| Bendandi, M | 5 |
| de Ridder, M | 1 |
| van der Lelie, H | 1 |
| Nieuwenhuis, K | 2 |
| Schouten, H | 1 |
| Mulder, A | 1 |
| van Reijswoud, I | 1 |
| Hop, W | 2 |
| Lowenberg, B | 3 |
| Cabanillas, FC | 1 |
| Velasquez, W | 1 |
| Bezwoda, W | 1 |
| Rastogi, RB | 1 |
| Erazo Valla, A | 1 |
| Pavlovsky, S | 2 |
| Morioka, H | 1 |
| Resegotti, L | 1 |
| Rueckle, H | 1 |
| Somoza, N | 2 |
| Moreno-Nogueira, JA | 1 |
| Kawano, Y | 1 |
| Takaue, Y | 1 |
| Saito, S | 1 |
| Sato, J | 1 |
| Shimizu, T | 1 |
| Suzue, T | 1 |
| Hirao, A | 1 |
| Okamoto, Y | 1 |
| Abe, T | 1 |
| Watanabe, T | 1 |
| Kohda, K | 1 |
| Tsuji, A | 1 |
| Takayanagi, N | 1 |
| Takeda, M | 1 |
| Hayashi, S | 1 |
| Takimoto, R | 1 |
| Fujisaki, Y | 1 |
| Tsuji, Y | 1 |
| Ezoe, A | 1 |
| Nakazawa, O | 1 |
| Lepage, E | 4 |
| Gisselbrecht, C | 4 |
| Haioun, C | 3 |
| Sebban, C | 2 |
| Tilly, H | 3 |
| Bosly, A | 3 |
| Morel, P | 3 |
| Herbrecht, R | 2 |
| Reyes, F | 3 |
| Coiffier, B | 3 |
| Takeshima, M | 1 |
| Nakamura, S | 1 |
| Mochizuki, Y | 1 |
| Hattori, N | 1 |
| Kaya, H | 1 |
| Otake, S | 1 |
| Okabe, Y | 1 |
| Okumura, H | 1 |
| Yoshida, T | 1 |
| Khalil, A | 1 |
| Ciobanu, N | 1 |
| Sparano, JA | 1 |
| Gucalp, R | 1 |
| Abate, G | 1 |
| Tafuto, S | 1 |
| Marcacci, G | 1 |
| Corazzelli, G | 1 |
| Fimiani, P | 1 |
| Monda, VM | 1 |
| Gailli, E | 1 |
| D'Andrea, P | 1 |
| Iaccarino, G | 1 |
| Bernard, T | 1 |
| Johnson, SA | 1 |
| Prentice, AG | 1 |
| Jones, L | 1 |
| Phillips, MJ | 1 |
| Newland, AC | 1 |
| Buzzoni, R | 2 |
| Colleoni, M | 1 |
| Nelli, P | 1 |
| Nolè, F | 1 |
| Bajetta, E | 2 |
| Obrist, R | 1 |
| Coutts, A | 1 |
| Fletcher, J | 1 |
| Toghill, PJ | 1 |
| Moloney, AJ | 1 |
| Hulman, G | 1 |
| Jenkins, D | 1 |
| Tirelli, U | 4 |
| Zagonel, V | 3 |
| Sorio, R | 1 |
| Talamini, R | 2 |
| Carbone, A | 2 |
| Monfardini, S | 2 |
| Goss, PE | 1 |
| Burkes, R | 2 |
| Rudinskas, L | 2 |
| King, M | 2 |
| Chow, W | 2 |
| Myers, R | 2 |
| Davidson, M | 2 |
| Poldre, P | 2 |
| Crump, M | 2 |
| Sutton, D | 2 |
| Schlaifer, D | 2 |
| Attal, M | 2 |
| Huguet, F | 2 |
| Canal, P | 2 |
| Laurent, G | 2 |
| Pris, J | 1 |
| Koch, P | 3 |
| Nahler, M | 4 |
| Herrmann, R | 4 |
| Mulder, AH | 1 |
| Michiels, JJ | 2 |
| Blijham, G | 1 |
| van de Lelie, J | 1 |
| Raemakers, JW | 1 |
| van der Heul, C | 1 |
| Redman, JR | 1 |
| Keating, M | 1 |
| Lafioniatis, SN | 1 |
| Bezwoda, WR | 1 |
| Bezwoda, MA | 1 |
| Seymour, L | 1 |
| Dansey, R | 1 |
| Ariad, S | 1 |
| Prescott, RJ | 1 |
| Leonard, RC | 1 |
| Matsuura, Y | 1 |
| Nakamura, H | 1 |
| Kogure, K | 1 |
| Fukazawa, M | 1 |
| Okuyama, Y | 1 |
| Kawano, E | 1 |
| Ishii, A | 1 |
| Nishimura, M | 1 |
| Hashimoto, S | 1 |
| Oh, H | 1 |
| Haak, HL | 1 |
| Gerrits, WB | 1 |
| Kerkhofs, H | 1 |
| Chatelut, E | 1 |
| Guichard, S | 1 |
| Muller, C | 1 |
| Houin, G | 1 |
| Bugat, R | 1 |
| Ansell, SM | 1 |
| Falkson, G | 2 |
| Chisesi, T | 3 |
| Cheson, BD | 1 |
| Görich, J | 1 |
| Brensing, KA | 1 |
| Kunze, V | 1 |
| Sokiranski, R | 1 |
| Rilinger, N | 1 |
| Müller-Miny, H | 1 |
| Brambs, HJ | 1 |
| Phillips, JK | 1 |
| Sherlaw-Johnson, C | 1 |
| Clough, JV | 1 |
| Parry, H | 1 |
| Nash, JR | 1 |
| Cawley, JC | 1 |
| Goss, P | 1 |
| Long, GD | 1 |
| Negrin, RS | 2 |
| Hoyle, CF | 1 |
| Kusnierz-Glaz, CR | 1 |
| Schriber, JR | 1 |
| Blume, KG | 2 |
| Chao, NJ | 1 |
| Landys, KE | 2 |
| Berg, GE | 1 |
| Torgerson, JS | 1 |
| Klingenstierna, HA | 1 |
| Ridell, BS | 1 |
| Johansson, BR | 1 |
| Wang, WS | 2 |
| Tzeng, CH | 3 |
| Chiou, TJ | 3 |
| Liu, JH | 3 |
| Fan, S | 1 |
| Chen, PM | 3 |
| Döhner, H | 1 |
| Murea, S | 2 |
| Spina, M | 1 |
| Gastaldi, R | 1 |
| Nigra, E | 1 |
| Nosari, AM | 1 |
| Magnani, G | 1 |
| Vaccher, E | 1 |
| Tiemann, M | 2 |
| Parwaresch, R | 2 |
| Stein, H | 2 |
| Trümper, L | 2 |
| Reuss-Borst, M | 2 |
| Tirier, C | 1 |
| Neubauer, A | 2 |
| Kreuser, ED | 2 |
| Dietzfelbinger, H | 1 |
| Engert, A | 1 |
| Stauder, R | 1 |
| Eimermacher, H | 1 |
| Landys, K | 2 |
| Saven, A | 1 |
| Lee, T | 1 |
| Kosty, M | 1 |
| Piro, L | 1 |
| Pettelot, G | 1 |
| Gibelin, P | 1 |
| Blanc, P | 1 |
| Hoffman, P | 1 |
| Fuzibet, JG | 1 |
| Ferrari, E | 1 |
| Baudouy, M | 1 |
| Morand, P | 1 |
| Izumi, T | 1 |
| Ohtsuki, T | 1 |
| Ohya, K | 1 |
| Ogawa, Y | 1 |
| Yoshida, M | 3 |
| Muroi, K | 1 |
| Imagawa, S | 1 |
| Hatake, K | 1 |
| Kuriki, K | 1 |
| Saito, K | 1 |
| Miura, Y | 1 |
| Bellesi, G | 1 |
| Stefanacci, S | 1 |
| Innocenti, F | 1 |
| Fusco, II | 1 |
| Di Lollo, S | 1 |
| Ferrini, PR | 1 |
| Brittinger, G | 1 |
| Meusers, P | 2 |
| Nel, JS | 1 |
| Falkson, CI | 2 |
| Bastion, Y | 1 |
| Brice, P | 1 |
| Dupriez, B | 3 |
| Nouvel, C | 2 |
| Lederlin, P | 1 |
| Biron, P | 1 |
| Brière, J | 1 |
| Gaulard, P | 2 |
| Magagnoli, M | 4 |
| Venturi, S | 1 |
| Tabanelli, M | 2 |
| Liso, V | 1 |
| Luraschi, A | 1 |
| Saglietti, G | 1 |
| Ferrari, V | 1 |
| Fedeli, P | 1 |
| Ripamonti, G | 1 |
| Gioria, A | 1 |
| Bersi, M | 1 |
| Merla, E | 1 |
| Hsieh, RK | 2 |
| Yen, CC | 1 |
| Ballestrero, A | 2 |
| Ferrando, F | 2 |
| Garuti, A | 2 |
| Basta, P | 1 |
| Gonella, R | 2 |
| Esposito, M | 1 |
| Vannozzi, MO | 1 |
| Sorice, G | 1 |
| Friedman, D | 1 |
| Puglisi, M | 1 |
| Brema, F | 1 |
| Mela, GS | 1 |
| Sessarego, M | 2 |
| Patrone, F | 2 |
| Rodriguez-Monge, EJ | 1 |
| Hoskin, PJ | 1 |
| Aydogdu, I | 1 |
| Koc, H | 1 |
| Ilhan, O | 1 |
| Gurman, G | 1 |
| Akan, H | 1 |
| Beksac, M | 1 |
| Konuk, N | 1 |
| Uysal, A | 1 |
| Ozerol, E | 1 |
| Van Glabbeke, M | 1 |
| Teodorovic, I | 1 |
| Kluin-Nelemans, JC | 1 |
| Thomas, J | 1 |
| Bron, D | 1 |
| Rosti, G | 1 |
| Somers, R | 1 |
| Noordijk, EM | 1 |
| Keating, MJ | 1 |
| Merli, F | 1 |
| Federico, M | 1 |
| Avanzini, P | 1 |
| Ilariucci, F | 1 |
| Stelitano, C | 1 |
| Iannitto, E | 1 |
| Colombi, M | 1 |
| Vallisa, D | 1 |
| Santagati, G | 1 |
| Picinini, L | 1 |
| Wöltjen, HH | 1 |
| Terhardt-Kasten, E | 1 |
| Busch, M | 1 |
| Kaiser, U | 1 |
| Hanrath, RD | 1 |
| Middeke, H | 1 |
| Helm, G | 1 |
| Bairey, O | 1 |
| Gabbay, U | 1 |
| Blickstein, D | 1 |
| Stark, P | 1 |
| Prokocimer, M | 1 |
| Epstein, O | 1 |
| Shaklai, M | 1 |
| Lahav, J | 1 |
| Gómez, H | 1 |
| Colomer, R | 1 |
| Rodriguez-Diaz Pavón, J | 1 |
| Dong, K | 1 |
| Moon, T | 1 |
| Ilias, I | 1 |
| Foufopoulou, E | 1 |
| Celik, I | 1 |
| Güler, N | 1 |
| Ozyilkan, O | 1 |
| Hayran, M | 1 |
| Rafel, M | 1 |
| Esteve, J | 1 |
| Cervantes, F | 1 |
| Velasco, M | 1 |
| Serra, A | 1 |
| Campo, E | 1 |
| Montserrat, E | 1 |
| Yau, JC | 1 |
| Germond, C | 1 |
| Gluck, S | 1 |
| Cripps, C | 1 |
| Verma, S | 1 |
| Burns, BF | 1 |
| Koski, TM | 1 |
| Lister, DC | 1 |
| Goss, GD | 1 |
| Mayer, J | 1 |
| Korístek, Z | 1 |
| Vásová, I | 1 |
| Müllerová, I | 1 |
| Král, Z | 1 |
| Navrátil, M | 1 |
| Klabusay, M | 1 |
| Vorlícek, J | 1 |
| Vodvárka, P | 1 |
| Hejlová, N | 1 |
| Penka, M | 1 |
| Krahulcová, E | 1 |
| Tomíska, M | 1 |
| Adam, Z | 1 |
| Hájek, R | 1 |
| Kersten, MJ | 1 |
| Verduyn, TJ | 1 |
| Reiss, P | 1 |
| Evers, LM | 1 |
| de Wolf, F | 1 |
| van Oers, MH | 1 |
| Schulz, R | 1 |
| Martin, S | 2 |
| Benner, A | 1 |
| Plantier-Colcher, I | 1 |
| Simon, M | 1 |
| Detourmignies, L | 1 |
| Jouet, JP | 1 |
| Fenaux, P | 1 |
| Bauters, F | 1 |
| Bachier, C | 1 |
| Preti, H | 1 |
| Sarris, AH | 3 |
| Weber, D | 1 |
| Urbańska-Ryś, H | 1 |
| Krykowski, E | 1 |
| Bremnes, RM | 1 |
| Bremnes, Y | 1 |
| Dønnem, T | 1 |
| Rodriguez, J | 2 |
| Santiago, M | 1 |
| Bocchia, M | 1 |
| Tomlinson, J | 1 |
| Tighe, M | 1 |
| Johnson, S | 1 |
| Stone, R | 1 |
| Nicholson, AG | 1 |
| Rule, S | 1 |
| Haq, R | 1 |
| Sawka, CA | 1 |
| Franssen, E | 1 |
| Berinstein, NL | 1 |
| Tarella, C | 1 |
| Caracciolo, D | 1 |
| Corradini, P | 1 |
| Zallio, F | 1 |
| Ladetto, M | 1 |
| Cuttica, A | 1 |
| Rossi, G | 1 |
| Novero, D | 1 |
| Gavarotti, P | 1 |
| Pileri, A | 1 |
| Orcioni, GF | 1 |
| Cellini, C | 1 |
| Pileri, SA | 1 |
| Mounier, N | 1 |
| Cole, BF | 1 |
| Marit, G | 1 |
| Bouabdallah, R | 1 |
| Ravoet, C | 1 |
| Salles, G | 1 |
| Pantel, G | 1 |
| Weis, M | 1 |
| Schmidt, P | 1 |
| Ho, AD | 5 |
| Doorduijn, JK | 1 |
| Spruit, P | 1 |
| van't Veer, M | 1 |
| Budel, L | 1 |
| Ghio, R | 1 |
| Johnston, LJ | 1 |
| Stockerl-Goldstein, KE | 1 |
| Hu, WW | 1 |
| Hoppe, RT | 1 |
| Horning, SJ | 1 |
| Nair, JS | 1 |
| Traganos, F | 1 |
| Tse-Dinh, YC | 1 |
| Santini, G | 2 |
| Nati, S | 1 |
| Spriano, M | 1 |
| Gallamini, A | 1 |
| Pierluigi, D | 1 |
| Congiu, AM | 2 |
| Truini, M | 1 |
| Rubagotti, A | 1 |
| Vimercati, R | 1 |
| Rossi, E | 1 |
| Sertoli, MR | 1 |
| Mattei, D | 1 |
| Marino, G | 1 |
| Peters, FP | 1 |
| Lalisang, RI | 1 |
| Fickers, MM | 1 |
| Erdkamp, FL | 1 |
| Wils, JA | 1 |
| Houben, SG | 1 |
| Wals, J | 1 |
| Polistena, P | 1 |
| Contu, A | 2 |
| Coser, P | 1 |
| Indrizzi, L | 1 |
| Leoni, P | 1 |
| Majolino, I | 1 |
| Porcellini, A | 1 |
| Zambaldi, G | 1 |
| Rizzoli, V | 1 |
| Mainwaring, PN | 1 |
| Gregory, W | 1 |
| Norton, AJ | 1 |
| Hudson, GV | 1 |
| Błoński, JZ | 1 |
| Kasznicki, M | 1 |
| Wilder, RB | 1 |
| Tucker, SL | 1 |
| Ha, CS | 1 |
| Hess, MA | 1 |
| Cabanillas, FF | 1 |
| Cox, JD | 1 |
| Kröger, N | 1 |
| Kroschinsky, F | 1 |
| Herbst, R | 1 |
| Naumann, R | 1 |
| Friedrichsen, K | 1 |
| Ehninger, G | 1 |
| Zander, AR | 1 |
| Ribeiro, RC | 1 |
| Fletcher, BD | 1 |
| Kennedy, W | 1 |
| Harrison, PL | 1 |
| Neel, MD | 1 |
| Kaste, SC | 1 |
| Sandlund, JT | 1 |
| Rubnitz, JE | 1 |
| Razzouk, BI | 1 |
| Relling, MV | 1 |
| Pui, CH | 1 |
| Vose, J | 1 |
| Modiano, M | 1 |
| Kraemer, K | 1 |
| Rifkin, R | 1 |
| Rubin, A | 1 |
| Menduni, T | 1 |
| Ghalie, R | 1 |
| Lichtman, SM | 1 |
| Kolitz, J | 1 |
| Budman, DR | 1 |
| Schulman, P | 1 |
| Vinciguerra, V | 1 |
| Hoffman, M | 1 |
| Mittelman, A | 1 |
| Allen, SL | 1 |
| Fusco, D | 1 |
| Hayes, FA | 1 |
| Niitsu, N | 1 |
| Iijima, K | 1 |
| Chizuka, A | 1 |
| Picozzi, VJ | 1 |
| Pohlman, BL | 1 |
| Lawless, GD | 1 |
| Lee, MW | 1 |
| Kerr, RO | 1 |
| Ford, JM | 1 |
| Fridman, M | 1 |
| Carter, WB | 1 |
| Seymour, JF | 1 |
| Grigg, AP | 1 |
| Szer, J | 1 |
| Fox, RM | 1 |
| Siemens, HJ | 1 |
| Gerke, P | 1 |
| Steinhoff, J | 1 |
| Roth-Isigkeit, A | 1 |
| Wagner, K | 1 |
| Brückner, S | 1 |
| Jiang, Y | 1 |
| Thomaides, A | 1 |
| Rassidakis, GZ | 1 |
| Ford, RJ | 1 |
| Medeiros, LJ | 1 |
| Kiamouris, C | 1 |
| Fillet, G | 1 |
| Divine, M | 1 |
| Deconninck, E | 1 |
| Bordessoule, D | 1 |
| Wilder, DD | 1 |
| Ogden, JL | 1 |
| Jain, VK | 1 |
| Mellou, S | 1 |
| Samantas, E | 1 |
| Papadopoulos, A | 1 |
| Papageogriou, E | 1 |
| Papasavvas, P | 1 |
| Endrizzi, L | 1 |
| Schintu, GM | 1 |
| Olmeo, N | 1 |
| Aversa, SM | 1 |
| Chiarion-Sileni, V | 1 |
| Sorarù, M | 1 |
| Fiorentino, MV | 1 |
| Saito, H | 1 |
| Mizoguchi, H | 1 |
| Baskal, N | 1 |
| Erdogan, G | 1 |
| Kamel, AN | 1 |
| Dagci, SS | 1 |
| Akyar, S | 1 |
| Ekinci, C | 1 |
| Kruglova, GV | 1 |
| Demina, EA | 1 |
| Evtushenko, VV | 1 |
| Wunsch-Zeddies, S | 1 |
| Schäfers, M | 1 |
| Wysk, J | 1 |
| Seidel, I | 1 |
| Hanauske, AR | 1 |
| Link, H | 1 |
| Schmoll, HJ | 1 |
| Poliwoda, H | 1 |
| Santarelli, MT | 2 |
| Erazo, A | 1 |
| Diaz Maqueo, JC | 1 |
| Lluesma Goñalons, M | 1 |
| Cervantes, G | 1 |
| Garcia Vela, EL | 1 |
| Corrado, C | 1 |
| Magnasco, H | 1 |
| Takagi, T | 1 |
| Sakai, C | 1 |
| Oguro, M | 1 |
| Case, DC | 2 |
| Carey, RW | 1 |
| Anderson, J | 1 |
| Gottlieb, A | 1 |
| Guglielmi, C | 1 |
| Amadori, S | 1 |
| Mandelli, F | 1 |
| De Cicco, M | 1 |
| van de Loo, J | 2 |
| Gao, HR | 2 |
| Paradiso, A | 1 |
| Guida, M | 1 |
| Berardi, F | 1 |
| Stehle, B | 1 |
| Weiss, C | 1 |
| Merk, K | 1 |
| Ideström, K | 1 |
| Johansson, B | 1 |
| Kimby, E | 1 |
| Lindemalm, C | 1 |
| Silver, RT | 1 |
| Wheeler, RH | 1 |
| Stein, RS | 1 |
| Stuart, JJ | 1 |
| Peterson, BA | 1 |
| Rivkin, SE | 1 |
| Golomb, HM | 1 |
| Jungerová, J | 1 |
| Koza, V | 1 |
| Cepelák, V | 1 |
| Del Valle, F | 3 |
| Engelhard, M | 2 |
| Rückle, H | 3 |
| Schlimok, G | 3 |
| Thiel, E | 3 |
| Andreesen, R | 2 |
| Fiedler, W | 2 |
| Watkin, SW | 1 |
| Green, JA | 1 |
| Nissen, NI | 1 |
| Hansen, SW | 1 |
| Ruit, JB | 1 |
| Hagenbeek, A | 1 |
| Verhoef, GE | 1 |
| Wielenga, JJ | 1 |
| Michiels, J | 1 |
| Sizoo, W | 1 |
| Schwammborn, J | 1 |
| Dörken, B | 2 |
| Laporte, JP | 1 |
| Godefroy, W | 1 |
| Verny, A | 1 |
| Gorin, NC | 1 |
| Najman, A | 1 |
| Duhamel, G | 1 |
| von Herbay, A | 1 |
| Mall, G | 1 |
| Körbling, M | 1 |
| Chuang, MW | 1 |
| Chiu, CF | 1 |
| Valagussa, P | 1 |
| Bonadonna, G | 1 |
| Vorobiof, DA | 1 |
| Terblanche, AP | 1 |
| Kimura, I | 3 |
| Ohnoshi, T | 3 |
| Masaoka, T | 1 |
| Sampi, K | 1 |
| Namba, K | 1 |
| Ueoka, H | 2 |
| Yamane, T | 2 |
| Ueno, K | 2 |
| Murashima, M | 2 |
| Tada, A | 2 |
| Keller, JW | 1 |
| Omura, GA | 1 |
| Gams, RA | 1 |
| Bartolucci, AA | 1 |
| Foss-Abrahamsen, A | 1 |
| Lenner, P | 1 |
| Hedenus, M | 1 |
| Noppa, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab in Patients With Low Grade Non-Hodgkins Lymphoma: An Analysis of Efficacy and Tolerability[NCT00208975] | Phase 2 | 15 participants (Actual) | Interventional | 2002-07-31 | Terminated (stopped due to slow accrual) | ||
| Phase II Study Treatment of High Risk Non-Hodgkin's Lymphomas[NCT00869284] | Phase 2 | 45 participants (Actual) | Interventional | 1994-10-31 | Completed | ||
| Phase II Study for Use of Oral Fludarabine Plus Cyclophosphamide and Rituximab Followed by Zevalin as Front-Line Treatment for Non-Follicular Indolent Lymphomas.[NCT00354822] | Phase 2 | 25 participants (Actual) | Interventional | 2005-08-31 | Terminated (stopped due to Inability to recruit in time a sufficient number of patients) | ||
| A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)[NCT00779883] | Phase 1 | 9 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase 1B Extension Trial to Allow Repeat Dosing of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Subjects Previously Treated in MDACC Protocol 2004-0914[NCT00783588] | Phase 1 | 4 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Phase II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rit[NCT00859001] | Phase 2 | 55 participants (Actual) | Interventional | Completed | |||
| Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib (EPOCH-R-B) Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics[NCT00114738] | Phase 2 | 53 participants (Actual) | Interventional | 2005-06-15 | Completed | ||
| A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma[NCT03151044] | Phase 3 | 408 participants (Anticipated) | Interventional | 2016-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Response (CR): Disappearance of all clinical evidence of active tumor for a minimum of eight weeks and absence of any symptoms related to the tumor.~Partial Response (PR):50% decrease in the sum of the product diameters of all lesions that persist for at least four weeks. No lesion can increase in size and no new lesion can appear during this period.~Stable disease (SD):A tumor that is neither growing nor shrinking.No new tumors have developed" (NCT00208975)
Timeframe: 6 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | |
| Chronic Lymphocytic Leukemia | 4 | 2 | 1 |
| Non Hodgkin Lymphoma | 5 | 2 | 0 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00114738)
Timeframe: Date treatment consent signed to date off study, approximately 143 months and 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| EPOCH-R+Bortezomib | 53 |
Overall Survival is the time between the first day of treatment to the day of death. The primary evaluation will be a Kaplan-Meier analysis with a two tailed log rank test. (NCT00114738)
Timeframe: up to 9.9 years
| Intervention | Months (Median) |
|---|---|
| EPOCH-R+Bortezomib | 80.4 |
Time interval from start of treatment to documented evidence of disease progression. Progression is defined by at least one of the following: ≥50% increase in the sum of the products of at least two lymph nodes, appearance of new lymph nodes, ≥50% increase in the size of the liver and/or spleen as determined by measurement below the respective costal margin, appearance of new palpable hepatomegaly or splenomegaly that was not previously present, and ≥50% increase in the absolute number of circulating lymphocytes. (NCT00114738)
Timeframe: up to 9.9 years
| Intervention | Months (Median) |
|---|---|
| EPOCH-R+Bortezomib | 29.3 |
Overall Survival is the time between the first day of treatment to the day of death. The primary evaluation will be a Kaplan-Meier analysis with a two tailed log rank test. (NCT00114738)
Timeframe: up to 9.9 years
| Intervention | Months (Median) |
|---|---|
| Bortezomib Maintenance | 78.6 |
| Observation | 87.5 |
| Not Randomized | 31.6 |
Time interval from start of treatment to documented evidence of disease progression. Progression is defined by at least one of the following: ≥50% increase in the sum of the products of at least two lymph nodes, appearance of new lymph nodes, ≥50% increase in the size of the liver and/or spleen as determined by measurement below the respective costal margin, appearance of new palpable hepatomegaly or splenomegaly that was not previously present, and ≥50% increase in the absolute number of circulating lymphocytes.The primary evaluation will be a Kaplan-Meier analysis with a two tailed log rank test. (NCT00114738)
Timeframe: up to 5 years
| Intervention | Months (Median) |
|---|---|
| Bortezomib Maintenance | 27.2 |
| Observation | 33.5 |
| Not Randomized | 7.8 |
Clinical response is assessed by the response criteria for lymphomas and is defined as a fraction of patients who have a complete response (CR) or a complete response (CR) + partial response (PR). A complete response is disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities (e.g. lactate dehydrogenase) definitely assignable to the lymphoma. Partial response is ≥50% decreased in the sum of the products of the greatest diameters of 6 largest dominant nodes or nodal masses. No increase in size of nodes, liver or spleen and no new sites of disease. Progressive disease is defined by at least one of the following: ≥50% increase in the sum of the products of at least two lymph nodes appearance of new lymph nodes, ≥50% increase in the size of the liver and/or spleen, ≥50% increase in the absolute number of circulating lymphocytes. (NCT00114738)
Timeframe: up to 22 weeks after initiation of therapy
| Intervention | Percentage of patients (Number) | ||||
|---|---|---|---|---|---|
| Overall Response (CR+PR) | Complete Response | Stable Disease | Progressive Disease | Not Evaluable | |
| EPOCH-R+Bortezomib | 92.5 | 86.7 | 3.8 | 1.9 | 1.9 |
15 reviews available for mitoxantrone and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodie | 2002 |
Updated meta analysis finds that interferon-alpha improves progression-free and overall survival in low-grade non-Hodgkin's lymphoma when administered with chemotherapy that contains anthracycline or mitoxantrone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Clinical Trials as Topic; D | 2002 |
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2003 |
Primary adrenal lymphoma presenting as Addison's disease: case report and review of the literature.
Topics: Addison Disease; Adrenal Cortex Neoplasms; Aged; Aged, 80 and over; Antineoplastic Combined Chemothe | 2004 |
Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, | 2004 |
Non-Hodgkin's lymphoma in the elderly. Part 2: treatment of diffuse aggressive lymphomas.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic | 2007 |
CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Non | 2008 |
The treatment of non-Hodgkin's lymphoma with mitoxantrone-containing regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphom | 1995 |
Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgk | 1994 |
Factors that influence prognosis of intermediate-grade lymphomas at relapse.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cisplatin; | 1996 |
High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Administr | 1997 |
Low-grade non-Hodgkin's lymphoma--development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Dexamethas | 1997 |
[Treatment of lymphoma in the aged].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubi | 1998 |
[Primary MALT-type lymphoma of the breast].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1998 |
Localized non-Hodgkin's lymphoma of the adrenal and thyroid glands.
Topics: Addison Disease; Adrenal Gland Neoplasms; Adrenal Glands; Adrenocorticotropic Hormone; Antineoplasti | 1992 |
121 trials available for mitoxantrone and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Huma | 2017 |
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2015 |
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP r
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cycl | 2008 |
Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarab | 2009 |
Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; D | 2009 |
Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2010 |
Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Disease-Free Survival; Fema | 2002 |
A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cy | 2002 |
Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 2002 |
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Cispla | 2002 |
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites; Antine | 2002 |
Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigen | 2002 |
A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2003 |
Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2003 |
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 2002 |
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2003 |
Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2003 |
Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2003 |
A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disea | 2003 |
First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2003 |
Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2004 |
Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lymphoma, Non-H | 2004 |
Parental longevity and prognosis in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
[VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Drug Administrati | 2005 |
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Su | 2005 |
Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncolo
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2005 |
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free | 2005 |
Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Pr | 2004 |
Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation: a salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Drug Res | 2006 |
A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyc | 2006 |
Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclopho | 2007 |
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2007 |
Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2007 |
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Fem | 2008 |
Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zo | 2008 |
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modali | 2008 |
Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphoma.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tra | 1993 |
Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomark | 1994 |
Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Dise | 1994 |
CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
Topics: Actuarial Analysis; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocol | 1995 |
FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sc | 1995 |
Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1995 |
Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 1995 |
[NEO-MACOP-B chemotherapy for the treatment of advanced-stage aggressive non-Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Eto | 1993 |
Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone | 1993 |
[MMIP chemotherapy for the treatment of the relapsed and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifos | 1995 |
Pilot study of high-dose mitoxantrone and busulfan plus autologous bone transplantation in patients with advanced malignancies.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Trans | 1995 |
Mitoxantrone, chlorambucil and prednisolone in the treatment of non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Humans; Lymphoma, | 1994 |
Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cis | 1994 |
Non-Hodgkin's lymphoma in elderly patients: a phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate- or high-grade histology.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1994 |
Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1994 |
Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgk | 1994 |
New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphom
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Germany; | 1994 |
Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1994 |
Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Hematopoiesis; Humans; Lympho | 1994 |
NOPE for relapsed aggressive diffuse non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Heart Failure; Humans; Lymphoma, | 1993 |
Pilot study and randomised trial of mitozantrone and ifosfamide for relapsed non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma group (SNLG) Working Party on Therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Lymphoma, N | 1993 |
[A combination chemotherapy of mitoxantrone, etoposide, carboplatin, and prednisolone (MECP) in recurrent or refractory non-Hodgkin's lymphomas].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1994 |
Mitoxantrone, teniposide, chlorambucil and prednisone (MVLP) for relapsed non-Hodgkin's lymphoma. The impact of advanced age and performance status.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophospha | 1993 |
Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas.
Topics: Adult; Dose-Response Relationship, Drug; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; M | 1993 |
A phase II trial of a chemotherapy combination in elderly patients with aggressive lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide | 1993 |
The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cyclophosphamide; | 1993 |
P-COMM-B induction chemotherapy in intermediate and high grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1995 |
A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etopo | 1995 |
High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Lymphoma, N | 1996 |
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Diseases; Carmu | 1996 |
Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; HIV Infections; Humans; Ly | 1996 |
Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 1996 |
A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etopo | 1996 |
Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Combined Modal | 1996 |
Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1997 |
Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etop | 1997 |
Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; | 1997 |
High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Administr | 1997 |
High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Surviv | 1997 |
Weekly chemotherapy using PMitCEBO in the palliation of recurrent non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1997 |
CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-F | 1998 |
Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1998 |
Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 1998 |
Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; | 1998 |
Phase II trial of MINE as a front-line therapeutic modality in intermediate- and high-grade non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; | 1998 |
Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, N | 1998 |
[Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etopos | 1998 |
Treatment of AIDS-related non-Hodgkin's lymphoma with chemotherapy (CNOP) and r-hu-G-CSF: clinical outcome and effect on HIV-1 viral load.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Granulocyte Colony- | 1998 |
The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytara | 1999 |
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabin | 1998 |
Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Dexamethasone; Female; Huma | 1999 |
Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; | 1999 |
Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; D | 1999 |
Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; | 1999 |
Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Female; Humans; Lymphoma, | 2000 |
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow | 2000 |
Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Ma | 2000 |
High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclo | 2000 |
Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymph | 2001 |
Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients.
Topics: Actuarial Analysis; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophospham | 2001 |
Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 2001 |
Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Cyclophospha | 2001 |
Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2001 |
Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Fr | 2001 |
Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dise | 2001 |
Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, N | 2001 |
Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Mobiliz | 2001 |
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
Topics: Actins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2002 |
Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymp | 2002 |
Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug | 2001 |
Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; De | 2002 |
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 1992 |
Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: cancer and leukemia group B study 8753.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 1992 |
Phase III comparative trial (m-BACOD v m-BNCOD) in the treatment of stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; | 1990 |
A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocol | 1992 |
Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease.
Topics: Drug Evaluation; Female; Heart; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; | 1991 |
Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colony-Stimulating Factors; | 1990 |
High activity of daily-schedule mitoxantrone in newly diagnosed low-grade non-Hodgkin's lymphomas: a 5-year follow-up.
Topics: Adult; Aged; Drug Administration Schedule; Female; Follow-Up Studies; Gated Blood-Pool Imaging; Huma | 1990 |
[Phase II clinical trial on mitoxantrone].
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Drug Evaluation; Female; Humans; Leukopenia; Lymphoma, No | 1989 |
[Mitoxantrone containing multi-drug chemotherapy in the management of malignancies. Collaborative Group for Clinical Trial of Mitoxantrone].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Digestive System Neoplasms; | 1989 |
Mitoxantrone: an active agent in refractory non-Hodgkin's lymphomas.
Topics: Adult; Aged; Clinical Trials as Topic; Doxorubicin; Female; Humans; Infusions, Intravenous; Lymphoma | 1988 |
[Mitoxantrone-containing combination chemotherapy in patients with non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 1986 |
87 other studies available for mitoxantrone and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Demographics and Outome in Paediatric Non-Hodgkin Lymphoma: Single Centre Experience at The Children Hospital Lahore, Pakistan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 2018 |
Substitution of mitoxantrone for doxorubicin in a multidrug chemotherapeutic protocol for first-line treatment of dogs with multicentric intermediate- to large-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2019 |
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2015 |
Clinical investigations in aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2008 |
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Murine-Derived; Anti | 2011 |
CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Topics: Acute Disease; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, Myelomonocytic; Antigen | 2002 |
CNOP for diffuse aggressive non-Hodgkin's lymphoma: the Nebraska lymphoma study group experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2002 |
A relapsed non-Hodgkin lymphoma presenting as panhypopituitarism successfully treated by chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Female | 2002 |
Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2003 |
Urinary immunocytology for primary bladder B cell lymphoma.
Topics: Aged; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocy | 2004 |
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2004 |
High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carboplatin; Disease | 2004 |
Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Di | 2005 |
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyt | 2005 |
An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
[Use of fludarabin in conjunction with other cytostatics in the treatment of non-Hodgkin lymphoma resistant to standard chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carm | 2005 |
Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Lomustine; Lympho | 2006 |
[Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2007 |
The effect of short-term intensive chemotherapy on reactivation of tuberculosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxo | 2007 |
[A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexa | 2007 |
Comment on: 'Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome'.
Topics: Administration, Oral; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Ble | 2008 |
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytar | 1995 |
Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosomes, Human, Pair 14; C | 1994 |
Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antineoplastic Agents; Ant | 1994 |
Intrapleural bleomycin in the treatment of chylothorax.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chylothorax; Cyclo | 1994 |
[Sequential high-dose therapy in patients with low-malignity non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Cytosine; Filgrastim; | 1995 |
Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine | 1995 |
Granulocyte colony-stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Cytarabine; Dau | 1993 |
Three-year results of MIM salvage treatment for refractory/relapsed intermediate grade NHL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrex | 1995 |
Aggressive non-Hodgkin's lymphoma in elderly patients: where to go from here?
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Su | 1994 |
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Chem | 1994 |
Low grade non-Hodgkin's lymphomas: disease control with mitoxanthrone monotherapy in patients refractory to conventional therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; | 1994 |
Clinical trials referral resource. Acute lymphocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clin | 1993 |
[Percutaneous drainage of refractory necrotizing tumors: experience in 9 patients].
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Cystadenocarcinoma; Drainage; Female; His | 1995 |
Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplasms; Cyclopho | 1995 |
Bulky centroblastic non-Hodgkin's lymphoma of the cranium vault mimicking brain involvement managed with chemotherapy: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cyclophosphamide; Diagnosis, Differ | 1995 |
Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Lymphoma, N | 1996 |
[Complete regression of cardiac non-Hodgkin's lymphoma after 23 months with chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Echocardiography; Electrocardiogra | 1996 |
Therapy-related leukemia with a novel 21q22 rearrangement.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosomes, Human, Pair 21; | 1996 |
Granulocyte-colony stimulating factor fails to prevent leucopenia caused by CEMP in elderly patients with aggressive lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide | 1996 |
[Primary extranodal non-Hodgkin's lymphoma of muscle tissue].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Extremities; Female; Follow- | 1997 |
Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Disease-Free S | 1997 |
Administration of MINE protocol in untreated patients with intermediate and high grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; | 1997 |
Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Combined Chemotherap | 1997 |
Onycholysis after chemotherapy in a patient with lymphoma.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Finge | 1998 |
The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosomes, Hum | 1998 |
High-grade non-Hodgkin's lymphoma treated in northern Norway--treatment, outcome, and prognostic factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined | 1999 |
Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1999 |
Interstitial pneumonitis following mitozantrone, chlorambucil and prednisolone (MCP) chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; H | 1999 |
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cycloph | 2000 |
In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2000 |
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bo | 2000 |
Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Topics: Acute Disease; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, | 2000 |
Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; | 2001 |
Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Arthroplasty, R | 2001 |
Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogen | 2001 |
Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-F | 2001 |
A prolonged APTT in a patient with a low grade malignant NHL - a case report.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Coagulation Factors; C | 2002 |
A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; | 1992 |
[Treatment of elderly patients with hematological malignancies].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1992 |
Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin | 1992 |
[The use of novantrone in combination with other preparations in hematosarcoma patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1992 |
Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, | 1992 |
[Combination chemotherapy with mitoxantrone, etoposide, vindesine and prednisolone for relapsed or refractory malignant lymphoma: presence of cross-resistance to CHOP therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Res | 1992 |
alpha Interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Inte | 1991 |
[Comparison of two multi-drug chemotherapy regimens based on mitoxantrone and epirubicin in 44 patients with non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubici | 1991 |
Experience with salvage regimens at M.D. Anderson Hospital.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Evaluation; Etoposide; F | 1991 |
Ifosfamide plus mitoxantrone as salvage treatment in non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; | 1991 |
Serum levels of tumor necrosis factor alpha in patients treated with granulocyte-macrophage colony-stimulating factor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colony-Stimulating Factors; Cytarabine; Granulocyte- | 1990 |
Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubic | 1991 |
[Injections of mitoxantrone, VUFB Praha, in the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma].
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myelo | 1991 |
Non-Hodgkin's lymphoma. A four-drug regimen suitable for elderly patients with advanced disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Drug Evaluation; Female; Humans; | 1990 |
Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administra | 1990 |
Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Doxorubicin; | 1990 |
Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Eval | 1990 |
Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Resp | 1990 |
Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation | 1989 |
Intrathecal mitozantrone.
Topics: Anthraquinones; Central Nervous System Diseases; Humans; Injections, Spinal; Lymphoma, Non-Hodgkin; | 1985 |
Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Cardiomyopat | 1988 |
[A comparative trial of C-novantrone OP(CNOP) vs C-adriamycin OP(CHOP) in the treatment of stage II-IV malignant lymphoma--the preliminary report].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1988 |
Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymp | 1988 |
Cyclophosphamide, mitoxantrone, vincristine and prednisone in the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodg | 1988 |
Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; L | 1987 |
Weekly mitoxantrone therapy of Hodgkin's disease, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. A Southeastern Cancer Study Group Trial.
Topics: Adolescent; Adult; Drug Administration Schedule; Drug Evaluation; Female; Hodgkin Disease; Humans; I | 1987 |
Mitoxantrone in the treatment of patients with non-Hodgkin's Lymphoma.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Heart Diseases; Hematopoiesis; Humans; Lympho | 1987 |
[Salvage chemotherapy of non-Hodgkin's lymphoma with a four-drug combination of mitoxantrone, etoposide, cisplatin and prednisolone (MEPP)].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etopos | 1987 |